Oct 05, 2010 9:00am EDT Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
Jul 02, 2009 9:00am EDT Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
Aug 19, 2008 8:15am EDT Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Jun 25, 2008 10:36am EDT Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
Feb 26, 2008 8:00am EST Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Sep 24, 2007 8:00am EDT Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
Jan 11, 2007 9:15am EST Lixte Biotechnology to Obtain High-Quality Tissue and Blood Samples from German University
